New platform targets specific cancer mutations to destroy proteins

A lipoprotein-biomimetic nanoplatform uses macropinocytosis to degrade proteins in KRAS-mutated cells.

Researchers developed KRASTAC, a lipoprotein-biomimetic nanoplatform. This platform targets KRAS-mutated (MT) tumor cells for protein degradation.

KRASTAC hijacks enhanced macropinocytosis in KRAS-MT cells. Macropinocytosis is a route for lysosome-targeting protein degradation.

The platform degrades proteins like epidermal growth factor receptor and programmed cell death ligand 1 (PD-L1). It works at a low antibody concentration of 2.52.5 nM within 99 h.

KRASTAC has minimal impact in KRAS wild-type (WT) cells. It shows mutation-specific tumor accumulation and protein degradation in vivo.

In mice with Kras-MT tumors, KRASTAC-induced PD-L1 degradation leads to robust antitumor efficacy. This also reprograms the immunosuppressive microenvironment.

Key facts

  • KRASTAC degrades proteins in KRAS-MT cells at 2.52.5 nM within 99 h.
  • The platform uses macropinocytosis to target the lysosome for protein degradation.
  • KRASTAC-induced PD-L1 degradation shows antitumor efficacy in mice with Kras-MT tumors.

All sections

Edition